Evidence map›Paper›PMID 37872574›Full record

ArticleBMC health services research2023

Cross-validation of comorbidity items in two national databases in a sample of patients with end-stage kidney disease.

Isabella Vanorio-Vega, Panayotis Constantinou, Assia Hami, Eric Cellarier, Antoine Rachas, Philippe Tuppin, Cécile Couchoud

Abstract read
In one paragraph

Article in BMC health services research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Isabella Vanorio-VegaDirection de La Stratégie Des Études Et Des Statistiques, Caisse Nationale de L'assurance Maladie (CNAM), Paris, Cedex 20, 75986, France. vanorio.i@gmail.com.ORCID http://orcid.org/0000-0003-4639-8862
Panayotis ConstantinouDirection de La Stratégie Des Études Et Des Statistiques, Caisse Nationale de L'assurance Maladie (CNAM), Paris, Cedex 20, 75986, France.ORCID http://orcid.org/0000-0003-4023-5915
Assia HamiCentre Hospitalier Universitaire de Nantes. PHU1-Institut de Transplantation Urologie Néphrologie (ITUN), Centre d'Hemodialyse Chronique- Aile Nord-Zone Administrative RCB, Nantes, France.
Eric CellarierCentre Hospitalier Universitaire Clermont-Ferrand, Hôpital Gabriel Montpied Département d'Information Médicale, Clermont-Ferrand, 63003, France.
Antoine RachasDirection de La Stratégie Des Études Et Des Statistiques, Caisse Nationale de L'assurance Maladie (CNAM), Paris, Cedex 20, 75986, France.ORCID http://orcid.org/0000-0001-9226-9071
Philippe TuppinDirection de La Stratégie Des Études Et Des Statistiques, Caisse Nationale de L'assurance Maladie (CNAM), Paris, Cedex 20, 75986, France.ORCID http://orcid.org/0000-0001-5698-9215
Cécile CouchoudAgence de La Biomédecine, 1 Avenue du Stade de France, Saint-Denis, 93212, France.ORCID http://orcid.org/0000-0002-9273-660X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe use of national medico-administrative databases for epidemiological studies has increased in the last decades. In France, the Healthcare Expenditures and Conditions Mapping (HECM) algorithm has been developed to analyse and monitor the morbidity and economic burden of 58 diseases. We aimed to assess the performance of the HECM in identifying different conditions in patients with end-stage kidney disease (ESKD) using data from the REIN registry (the French National Registry for patients with ESKD).

methodsWe included all patients over 18 years of age who started renal replacement therapy in France in 2018. Five conditions with a similar definition in both databases were included (ESKD, diabetes, human immunodeficiency virus [HIV], coronary insufficiency, and cancer). The performance of each SNDS algorithm was assessed using sensitivity, specificity, positive predictive values (PPVs), negative predictive values (NPVs), and Cohen's kappa coefficient.

resultsIn total 5,971 patients were included. Among them, 81% were identified as having ESKD in both databases. Diabetes was the condition with the best performance, with a sensitivity, specificity, PPV, NPV, and Kappa coefficient all over 80%. Cancer had the lowest level of agreement with a Kappa coefficient of 51% and a high specificity and high NPV (94% and 95%). The conditions for which the definition in the HECM included disease-specific medications performed better in our study.

conclusionThe HECM showed good to very good concordance with the REIN database information overall, with the exception of cancer. Further validation of the HECM tool in other populations should be performed.

Indexed as

Diabetes MellitusKidney Failure, ChronicNeoplasmsAdolescentAdultComorbidityDatabases, FactualHumansRegistriesAlgorithm validationComorbiditiesMedico-administrative databases

Identifiers

PMID37872574
PMCPMC10594771

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.